Helicos BioSciences Validates Performance of True Single Molecule Sequencing

Helicos BioSciences Corporation

Helicos BioSciences Validates Performance of True Single Molecule Sequencing

February 8, 2008

Life Science Company Presents Data at Advances in Genome Biology and Technology Meeting

CAMBRIDGE, Mass., Feb 08, 2008 (BUSINESS WIRE) -- Helicos BioSciences (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced two of its scientists will present performance and application data about the HeliScope(TM) Single Molecule Sequencer. William Efcavitch, PhD, senior vice president of product research and development, and Timothy Harris, PhD, senior director of research, will be featured speakers today at the Advances in Genome Biology and Technology (AGBT) meeting at the Marriott Resort and Golf Club in Marco Island, FL.

"The science unfolding this year at AGBT begins to demonstrate a future where sequence information will become more and more integral on our path to personalized healthcare. The Helicos team is pleased to be a valued presenter and sponsor at this meeting," said Patrice Milos, PhD, vice president and chief scientific officer at Helicos BioSciences. "We look forward to updating the scientific community on Helicos' accelerated research efforts and unprecedented tSMS(TM) technology. Our scientists will present compelling data about why Helicos has a scientific advantage especially in terms of our technology's reproducibility and high throughput."

Dr. Efcavitch will present data generated by True Single Molecule Sequencing, tSMS(TM), that will include sequencing of a BAC insert with an error rate of less than one percent. Dr. Efcavitch will also discuss how tSMS technology can successfully detect single nucleotide polymorphisms (SNPs) in pooled amplicons from human gene targets.

Dr. Harris will discuss single molecule sequencing of human brain miRNA. Details will be provided on the accurate enumeration of related miRNA families and the use of Helicos' sequencing depth to identify potentially new miRNA members. This study demonstrates the benefits offered by the proprietary Helicos technology - enumeration with a quantitative accuracy and reproducibility at an exceedingly lower cost and at a high throughput not achieved anywhere else.

Helicos is pleased to present this data, for the first time at the AGBT meeting. This unparalleled data will help to support our belief that Helicos' proprietary tSMS technology will lead to accurate diagnostics for cancer and other diseases, individualized drug therapies and personalized medical treatments.

About Helicos BioSciences:

Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing, tSMS(TM), Technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and committed to providing scientists the tools to unlock the era of genomic medicine. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617)264-1800. For more information, please visit www.helicosbio.com.

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, Helicos' expectations concerning the prospective value of the data and advances that will be presented by Helicos' employees at the AGBT conference discussed in this press release and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Helicos' control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, our ability to successfully complete the manufacturing process and commercialize the HeliScope system; competition; changing technology and customer requirements; our ability to operate in an emerging market; market acceptance of our technology; our ability to retain our personnel and hire additional skilled personnel; our ability to manage our rapid growth and our ability to obtain capital when desired on favorable terms. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Helicos undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Helicos, see the disclosure contained in Helicos' public filings with the Securities and Exchange Commission.

Investor Relations:

Helicos BioSciences Corporation
Louise Mawhinney, 617-264-1800
Sr. Vice President and Chief Financial Officer

Media Contact:

Racepoint Group
Sally Bain, 781-487-4647
sbain@racepointgroup.com